RZLT - NASDAQ

Rezolute, Inc.

RZLT·NASDAQ

$4.00

+14%

HealthcareBiotechnology

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$385.17M

EPS-0.9800

P/E Ratio-4.56

Earnings Date09/10/2026

175.49M

Assets

32%

3Y+15.0%

5Y+1500.0%

10Y+1509.0%

13.36M

Total Liabilities

14%

3Y+353.0%

5Y+271.0%

10Y+527.0%

162.13M

Total Equity

34%

3Y+8.0%

5Y+2101.0%

10Y+1748.0%

Rezolute, Inc. Funding & Solvency Profile

RZLT · NASDAQ

Current Assets

Cash & Cash Equivalents94.11M

Net Receivables0.00

Inventory0.00

Other Current Assets3.29M

Total Current Assets171 M

Non-Current Assets

Property, Plant & Equipment1.42M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets2.92M

Total Non-Current Assets4 M

Total Assets

175.49M

Financial Health Analysis

Current Ratio

14.37x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.08x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

159 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

98% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Rezolute, Inc. Balance Sheet

RZLT • NASDAQ

Rezolute, Inc. Balance Sheet	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jun 2017	Jun 2016	Jun 2015	Jun 2014	Jun 2013	Jun 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	94.1M	70.4M	16M	150.4M	41M	10M	11.6M	1.6M	4.5M	4.1M	5.3M	5.9M	527.0	5.1K
Short-Term Investments	73.8M	56.5M	85.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	167.9M	126.9M	101.9M	150.4M	41M	10M	11.6M	1.6M	4.5M	4.1M	5.3M	5.9M	527.0	5.1K
Net Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	350.5K	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	350.5K	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	67.2K	289.6K	223K	0.0
Prepaids	0.0	0.0	3M	1.7M	946K	563K	571K	362K	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	3.3M	1.8M	0.0	0.0	0.0	0.0	571K	361.9K	442K	430.1K	770.5K	83.4K	241.5K	0.0
Total Current Assets	171.1M	128.7M	104.9M	152.1M	42M	10.5M	12.1M	2M	4.9M	4.5M	6.1M	6.3M	815.5K	5.1K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.4M	2M	2.2M	168K	425K	416K	44K	368.4K	5.3M	6M	4.5M	337.9K	275.7K	0.0
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	29K	37K	44.3K	51.6K	58.9K	9.2K	12.7K	0.0
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	29K	37K	44.3K	51.6K	58.9K	9.2K	12.7K	0.0
Long-Term Investments	0.0	263K	16.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	2.9M	1.8M	148K	148K	191K	31K	35K	89.7K	330.6K	375K	563K	750K	0.0	0.0
Total Non-Current Assets	4.3M	4.1M	18.8M	316K	616K	447K	108K	495.1K	5.7M	6.4M	5.1M	1.1M	288.4K	0.0
Total Assets	175.5M	132.7M	123.7M	152.4M	42.6M	11M	12.3M	2.5M	10.6M	10.9M	11.3M	7.4M	1.1M	5.1K
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.8M	4.9M	3.3M	1.1M	1M	2.5M	1.1M	1.7M	926K	1.5M	1.4M	460.3K	188.3K	109.2K
Accounts Payable	5.8M	4.9M	3.3M	1.1M	1M	893K	563K	1.7M	926K	1.5M	1.4M	460.3K	188.3K	109.2K
Other Payables	0.0	0.0	0.0	0.0	0.0	1.6M	488K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	3.2M	2.3M	507K	1.2M	591K	368K	790K	771K	704.2K	15.1K	13.1K	11.1K	1.2M	110.1K
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	10K	3.4M	10K	83.1K	153.9K	60K	3.7M	0.0
Capital Lease Obligations (Current)	632K	568K	541K	108K	265K	245K	0.0	0.0	0.0	23.1K	93.9K	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1M	108.1K	15.1K	13.1K	408.1K	1.2M	0.0
Other Current Liabilities	2.3M	1.8M	883K	0.0	77K	120K	6.5M	335.9K	131.1K	108.5K	36.6K	432.7K	157.8K	-208.7K
Total Current Liabilities	11.9M	9.6M	5.2M	2.5M	2M	3.2M	8.4M	6.2M	1.8M	1.7M	1.7M	964K	5.3M	10.5K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	14M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	400K	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	468K	468K	412K	407K	387K	209K	2.1M	215.6K	329.6K	0.0	480.5K	33.9K	0.0	0.0
Total Non-Current Liabilities	1.5M	2.1M	2.3M	487K	14.5M	374K	2.1M	215.6K	329.6K	400K	503.6K	33.9K	3.9M	10.5K
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.9M	-10.5K
Capital Lease Obligations	1.6M	2.2M	2.5M	188K	452K	410K	28K	304.6K	409.9K	23.1K	117K	0.0	0.0	0.0
Total Liabilities	13.4M	11.7M	7.5M	2.9M	16.5M	3.6M	10.5M	6.5M	2.1M	2.1M	2.2M	997.9K	5.3M	10.5K
SHAREHOLDERS' EQUITY
Common Stock	87K	53K	37K	34K	8K	6K	210K	62.2K	49.2K	35.1K	24.3K	18.1K	40K	4.1K
Additional Paid-In Capital	565.9M	450.5M	377.5M	358.6M	194.2M	154.6M	128.7M	90.2M	72.8M	52.8M	38.1M	24.1M	3.8M	100.0
Retained Earnings	-403.9M	-329.4M	-261M	-209.2M	-168.1M	-147.2M	-126.9M	-94.2M	-64.3M	-44M	-29.1M	-17.7M	-8M	-91.2K
Accumulated Other Comprehensive Income/Loss	-7K	-79K	-351K	0.0	0.0	0.0	0.0	-517.8K	-2M	-879.3K	-136.6K	-7.8K	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-17.0	0.0	0.0	0.0	0.0	40K	-4.1M
Total Stockholders' Equity	162.1M	121M	116.2M	149.5M	26.1M	7.4M	1.8M	-4M	8.5M	8.8M	9.1M	6.4M	-4.2M	-5.4K
Total Equity	162.1M	121M	116.2M	149.5M	26.1M	7.4M	1.8M	-4M	8.5M	8.8M	9.1M	6.4M	-4.2M	-5.4K
SUMMARY
Total Liabilities & Equity	175.5M	132.7M	123.7M	152.4M	42.6M	11M	12.3M	2.5M	10.6M	10.9M	11.3M	7.4M	1.1M	5.1K
Total Investments	73.8M	56.7M	102.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	1.6M	2.2M	2.5M	188K	14.4M	410K	10K	3.4M	10K	83.1K	177K	60K	3.7M	0.0
Net Debt	-92.5M	-68.2M	-13.6M	-150.2M	-26.6M	-9.5M	-11.6M	1.8M	-4.5M	-4M	-5.1M	-5.9M	3.7M	-5.1K
Shares Outstanding	92,727,500	92,727,500	92,727,500	92,727,500	92,727,500	92,727,500	92,727,500	92,727,500	92,727,500	92,727,500	92,727,500	92,727,500	92,727,500	92,727,500

SEC Filings

RZLT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 02, 2026	June 02, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 12, 2026	February 12, 2026	2026	View Filing
10-Q 10-Q 2025 Q4 Q4	February 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 21, 2025	November 19, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 10, 2025	2025	View Filing

Showing 1 to 10 of 286 filings

Related Guides

Blog Categories

Continue your RZLT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.